- TRADE NAMES: Nubeqa (Bayer); ODM-201 (Bayer)
- INDICATIONS: Treatment of patients with non-metastatic castration-resistant prostate cancer. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
- SYNONYM: Nubeqa
- CLASS: Androgen receptor inhibitor, Anti-prostate cancer agent
- HALF-LIFE: 20 hours
- FDA APPROVAL DATE: 07/30/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCRP substrates, CYP3A inducers, CYP3A inhibitors - PREGNANCY: May cause fetal harm and loss of pregnancy when administered to a pregnant female. Males with female partners of reproductive potential are advised to use effective contraception during treatment and for 1 week after the last dose of darolutamide.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 09/25/2026
